

Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/V8AE9CA5B3FEN.html>

Date: April 2020

Pages: 56

Price: US\$ 125.00 (Single User License)

ID: V8AE9CA5B3FEN

Abstracts

Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vivus Inc (Vivus) is a biopharmaceutical company that develops and commercializes next-generation therapeutics for addressing unmet medical needs of obesity, sleep apnea, diabetes, and sexual health. The company markets phentermine and topiramate extended-release capsules for the chronic weight management in adult patients; avanafil, an oral phosphodiesterase type 5, for erectile dysfunction; and pancrelipase microtablets for exocrine pancreatic insufficiency. It is investigating its pipeline products for the treatment of obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, and pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product and pipeline portfolio. The company also has direct operations through its subsidiaries in Canada and the Netherlands. Vivus is headquartered in Campbell, California, the US.

Vivus Inc Key Recent Developments

Apr 03,2020 VitalTech partners with VIVUS Pharmaceuticals to accelerate launch of telehealth and remote patient monitoring modules

Apr 01,2020 VIVUS announces \$11.55 million registered direct offering priced at-the-market under Nasdaq Rules

Mar 31,2020 VIVUS accelerates the launch of telemedicine and remote monitoring

modules to facilitate effective patient care during “social distancing”

Mar 03,2020 VIVUS reports fourth quarter and full year 2019 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Vivus Inc - Key Facts
Vivus Inc - Key Employees
Vivus Inc - Key Employee Biographies
Vivus Inc - Major Products and Services
Vivus Inc - History
Vivus Inc - Company Statement
Vivus Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Vivus Inc - Business Description
Product Category: License and Milestone Revenue
Performance
Product Category: Pancreaze/ Pancreaze MT (Net Product and Royalty Revenue)
Performance
Product Category: Qsymia (Net Product and Supply Revenue)
Performance
Product Category: Stendra/Spedra (Supply and Royalty Revenue)
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
Vivus Inc - Corporate Strategy
Vivus Inc - SWOT Analysis
SWOT Analysis - Overview
Vivus Inc - Strengths
Vivus Inc - Weaknesses
Vivus Inc - Opportunities
Vivus Inc - Threats
Vivus Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

Vivus Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 03, 2020: VitalTech partners with VIVUS Pharmaceuticals to accelerate launch of telehealth and remote patient monitoring modules

Apr 01, 2020: VIVUS announces \$11.55 million registered direct offering priced at-the-market under Nasdaq Rules

Mar 31, 2020: VIVUS accelerates the launch of telemedicine and remote monitoring modules to facilitate effective patient care during “social distancing”

Mar 03, 2020: VIVUS reports fourth quarter and full year 2019 financial results

Nov 05, 2019: VIVUS reports third quarter 2019 financial results

Oct 28, 2019: VIVUS announces departures of Eric W. Roberts and Allan L. Shaw from Board of Directors

Aug 06, 2019: VIVUS reports second quarter 2019 financial results

Apr 30, 2019: VIVUS Reports First Quarter 2019 Financial Results

Feb 26, 2019: VIVUS announces fourth quarter 2018 financial results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Vivus Inc, Key Facts
Vivus Inc, Key Employees
Vivus Inc, Key Employee Biographies
Vivus Inc, Major Products and Services
Vivus Inc, History
Vivus Inc, Subsidiaries
Vivus Inc, Key Competitors
Vivus Inc, Ratios based on current share price
Vivus Inc, Annual Ratios
Vivus Inc, Annual Ratios (Cont...1)
Vivus Inc, Annual Ratios (Cont...2)
Vivus Inc, Interim Ratios
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Vivus Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Vivus Inc, Performance Chart (2015 - 2019)

Vivus Inc, Ratio Charts

Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Novo Nordisk AS

Boehringer Ingelheim International GmbH

AbbVie Inc

F. Hoffmann-La Roche Ltd

Merck & Co Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Pfizer Inc

Digestive Care Inc

Eli Lilly and Co

Nalpropion Pharmaceuticals Inc

Janssen Pharmaceuticals Inc

GlaxoSmithKline Plc

I would like to order

Product name: Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/V8AE9CA5B3FEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V8AE9CA5B3FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970